IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
Omnicell, Inc. is a global healthcare technology company that provides automation systems for medication management in healthcare settings and pharmacies. It offers automated dispensing systems for medications and supplies, central pharmacy dispensing services, IV compounding services through robotics technology, specialty pharmacy services, inventory optimization services, patient engagement, clinical, and financial solutions, medication adherence solutions, and professional services for health system pharmacies. It serves hospitals and retail pharmacies in the US, Canada, the United Kingdom, France, Germany, and Australia. The firm was incorporated in Delaware on April 14, 2000. Its headquarters are located in Fort Worth, Texas.
IBISWorld's SupplierIQ profile covering Omnicell Inc includes financial statements, products & service markets, competitive position and key financial health ratios.
This SupplierIQ profile on Omnicell Inc covers the company’s financial statements, products & service markets, competitive position and key financial health ratios. Omnicell Inc, trading as Omnicell, is a public company with 3.7k employees.
Omnicell Inc primarily operates in All Other Miscellaneous Ambulatory Health Care Services, as well as in Measuring, Testing & Navigational Instrument Manufacturing in the US.
The Product & Service Markets chapter provides a breakdown of Omnicell Inc’s key product and service segments, organized by standardized industry classifications like NAICS. It includes their market share in each of these markets with market share trends and insights.
The Competitive Position chapter covers Omnicell Inc’s performance relative to competitors in each of the products and service markets the company operates in. This includes a detailed competitor matrix comparing the market share, return on assets, return on equity, pricing power and competitive outlook. There are qualitative insights and a detailed SWOT analysis included for each product and service market.
The Income Statement chapter includes datasets covering Omnicell Inc’s historical financial performance. Line items include revenue, cost of sales, gross margins, general and administrative costs, research and development costs, depreciation, interest and taxes. This is available in current and historical datasets.
The Balance Sheet chapter includes datasets covering Omnicell Inc’s historical financial health. Current asset and non-current asset accounts include line items like cash, receivables, inventories, property, plant and equipment, investments, goodwill. Current liabilities and non-current liabilities accounts include line items like accounts payable, debts, provisions and lease liabilities. The equity accounts include line items like paid-in capital, retained earnings, employee stock option plans and treasury stock. This is available in current and historical datasets.
The Cash Flows chapter includes detailed line item accounts covering Omnicell Inc’s operating cash flow activities, financing cash flow activities and investing cash flow activities. This is available in current and historical datasets.
The Ratios chapter covers key financial metrics like the operating margin, gross margin, return on equity, return on assets, current ratio, quick ratio, EBIT margins, EBITDA margins, debt ratio, equity ratio and debt to equity ratios. This is available in current and historical datasets.
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
According to the 2026 IBISWorld ProcurementIQ report, Omnicell Inc generated $1.2bn in revenue.
The 2026 ProcurementIQ report benchmarks Omnicell Inc against its top competitors across execution score, operational capabilities, pricing power, and market share.
Omnicell Inc’s EBITDA margin is reported across a 7-year period in the 2026 IBISWorld ProcurementIQ report. The report includes a full income statement breakdown.
The 2026 report identifies all NAICS-coded product and service markets Omnicell Inc participates in, including market share, concentration, profitability trends, and average vendor risk ratings.
The 2026 ProcurementIQ report lists Omnicell Inc’s employee count and benchmarks workforce size against key competitors to assess relative operational capacity.